


Nodal Excisions & Neck Dissection Specimens for Head & Neck Tumours Histopathology Reporting Proforma



Includes the  International Collaboration on Cancer reporting dataset denoted by *

Family name

Given name(s)

Date of birth

Patient identifiers

e.g. MRN, IHI or NHI (please indicate which)

Date of request

S1.03 Accession number

Requesting doctor - name and contact details

Sex

- Male
 Female
 Intersex/indeterminate

Ethnicity

- Unknown
 Aboriginal/Torres Strait Islander (AU)
 Māori (NZ)
 Other ethnicity:

Clinical information

S1.02 Not provided OR

* Operative procedure (select all that apply)

Text, *specify*

- Level I
 Level II
 Level III
 Level IV
 Level V
 Level VI
 Level VII
 Levels I-IV
 Levels I-V
 Other, *specify*

Neoadjuvant therapy

- Information not provided
 Not administered
 Administered, *specify type (select all that apply)*

- Chemotherapy
 Radiotherapy
 Targeted therapy, *specify if available*

Immunotherapy, *specify if available*

Time interval since therapy, *specify*

Recurrence

Recurrence - regional, *describe*

Recurrence - distant, *describe*

Laterality

- Not specified
 Left Right Bilateral
 Other, *specify*

Previous treatment

G1.01 COPY TO DOCTORS

S1.04 PRINCIPAL CLINICIAN

G1.02 ADDITIONAL COMMENTS

Macroscopic findings

S2.01 SPECIMEN LABELLED AS

S2.02 SPECIMEN LATERALITY

- Not specified
 Left Right Bilateral
 Other, *specify*

G2.01 *Operative procedure (select all that apply)

- Not specified
 Level I
 Level II
 Level III
 Level IV
 Level V
 Level VI
 Level VII
 Levels I-IV
 Levels I-V
 Other, *specify*

S2.03 *SPECIMENS SUBMITTED (select all that apply)

- Lymph nodes
 Not specified
 Level IA
 Level IB
 Level II
 Level III
 Level IV
 Level V
 Level VI
 Level VII
 Levels I-IV
 Levels I-V
 Other, *specify*

Central compartment (VI +/- VII)

Non-lymphoid tissue

- Thymus
 Parathyroid
 Other, *specify*

Non-lymphoid tissue

- Nerve
 Muscle
 Vein
 Salivary gland
 Other, *specify*

Specimen laterality should be recorded for each specimen submitted (S2.02).

G2.02 SPECIMEN DIMENSIONS

Record for each specimen submitted

 mm x mm x mm

G2.03 NUMBER OF LYMPH NODES RETRIEVED

Record number for each lymph node site submitted

G2.04 MACROSCOPIC METASTATIC TUMOUR

- Not identified Present
If present, consider reporting G2.05 and G2.06.

G2.05 MAXIMUM DIMENSION OF LARGEST METASTATIC DEPOSIT

 mm

G2.06 MACROSCOPIC EVIDENCE OF EXTRACAPSULAR SPREAD

- Absent Present

G2.07 MACROSCOPIC DISTANCE OF TUMOUR TO CLOSEST MARGIN

 mm

S2.04 INK APPLICATION AND BLOCK IDENTIFICATION KEY

G2.08 ADDITIONAL MACROSCOPIC COMMENTS

Microscopic findings

S3.01 *HISTOLOGICAL TUMOUR TYPE (select all that apply)

(Value list from the World Health Organization Classification of Head and Neck Tumours (2017))

Squamous cell carcinoma (SCC)

- Squamous cell carcinoma, conventional
 HPV-mediated/p16 positive oropharyngeal carcinoma
 Basaloid squamous cell carcinoma
 Papillary squamous cell carcinoma
 Spindle cell squamous carcinoma (sarcomatoid carcinoma)
 Adenosquamous cell carcinoma
 Acantholytic squamous cell carcinoma
 Carcinoma cuniculatum
 Undifferentiated (lymphoepithelial) carcinoma

S3.01 * HISTOLOGICAL TUMOUR TYPE (Continued)

Salivary gland carcinoma

- Acinic cell carcinoma
- Secretory carcinoma
- Mucoepidermoid carcinoma
 - Low grade mucoepidermoid carcinoma
 - Intermediate grade mucoepidermoid carcinoma
 - High grade mucoepidermoid carcinoma
- Adenoid cystic carcinoma
 - Tubular/cribriform pattern predominant
 - Solid pattern >30%
- Polymorphous adenocarcinoma
 - Classic Cribriform

Grade, specify

- Epithelial-myoeplithelial carcinoma
- (Hyalinizing) Clear cell carcinoma
- Basal cell adenocarcinoma
- Sebaceous adenocarcinoma
- Intraductal carcinoma
 - Low grade High grade
- Cystadenocarcinoma
- Adenocarcinoma, not otherwise specified (NOS)
- Salivary duct carcinoma
- Myoepithelial carcinoma
- Carcinoma ex pleomorphic adenoma

Type(s), specify

- Carcinosarcoma
- Poorly differentiated carcinoma: Neuroendocrine and non-neuroendocrine
 - Undifferentiated carcinoma
 - Large cell neuroendocrine carcinoma
 - Small cell neuroendocrine carcinoma

- Lymphoepithelial carcinoma
- Squamous cell carcinoma
- Oncocytic carcinoma
- Other, specify

Neuroendocrine carcinoma

- Well-differentiated (typical carcinoid)
- Moderately differentiated (atypical carcinoid)
- Poorly differentiated (high grade neuroendocrine carcinoma), large cell type
- Poorly differentiated (high grade neuroendocrine carcinoma), small cell type

Nasopharyngeal carcinoma

- Squamous cell carcinoma, keratinizing
- Squamous cell carcinoma, non-keratinizing, differentiated
- Squamous cell carcinoma, non-keratinizing, undifferentiated
- Squamous cell carcinoma, basaloid
- Nasopharyngeal papillary adenocarcinoma

Sinonasal malignancies

Mucosal melanoma

Cutaneous malignancies

- Melanoma
- Squamous cell carcinoma
- Merkel cell carcinoma
- Sebaceous carcinoma
- Other primary adnexal malignancies, specify type

Other, specify types

G3.01 * PRIMARY TUMOUR SITE

- Not specified/unknown
- Specify site (e.g., oral cavity, larynx)

S3.02 LYMPH NODE LATERALITY

- Not specified
- Right
- Left
- Central
- Other, specify

Record laterality for each lymph node submitted. In the case of bilateral neck dissections, right and left neck dissections should be reported separately.

S3.03 * LYMPH NODE STATUS (select all that apply)

No. nodes examined	No. positive nodes	Soft tissue metastasis	ENE [^]
--------------------------	--------------------------	------------------------------	------------------

Node level

- Level IA
- Level IB
- Level II
- Level III
- Level IV
- Level V
- Level VI
- Level VII
- Levels I-IV
- Levels I-V

Other, specify

Level IA			
Level IB			
Level II			
Level III			
Level IV			
Level V			
Level VI			
Level VII			
Levels I-IV			
Levels I-V			

For each node level submitted, record number of nodes examined, number of nodes positive, presence of any soft tissue metastasis, extranodal extension, or if cannot be determined. Extranodal extension (ENE) is optional for HPV-related/p16 positive oropharyngeal cancer and nasopharyngeal cancer.

[^]If ENE is identified, record S3.04, G3.02 & G3.03.

Maximum dimension of largest lymph node metastasis (if applicable)

 mm

Maximum dimension of largest involved lymph node (if applicable)

mm

Specify site (level)

S3.04 * EXTRANODAL EXTENSION

- Not identified
- ENEmi (<2 mm)
- ENEma (>2 mm)

Extranodal extension (ENE) is optional for HPV-related/p16 positive oropharyngeal cancer and nasopharyngeal cancer.

G3.02 * Number of nodes with ENE

- Cannot be determined

G3.03 * Greatest extent of ENE

Specify site (level)

mm

G3.04 * Non-lymphatic structures involved

- Not identified
- Present, specify

G3.05 * MARGIN STATUS

Involvement of perinodal surgical margin

- Not involved by carcinoma
- Involved by carcinoma
 - Left Right
 - Central Laterality not specified
- Cannot be assessed, specify

G3.06 RADIATION INDUCED TISSUE DAMAGE

- Not identified
- Identified, specify (describe induced damage, if possible)

- Cannot be assessed, specify (describe reason, if possible)

G3.07 ADDITIONAL PATHOLOGIC FINDINGS

G3.08 ADDITIONAL MICROSCOPIC COMMENT

Ancillary findings

G4.01 * ANCILLARY STUDIES

- Not performed
- Performed, specify

Synthesis and overview

S5.01 * PATHOLOGICAL STAGING (AJCC 8th Edition)##

- r - recurrent
- y - post-therapy

For primary carcinomas of the lip and oral cavity, major salivary glands, nasal cavity and paranasal sinuses, oropharynx (p16 negative), hypopharynx, larynx, cutaneous head and neck carcinomas (with the exception of Merkel cell carcinoma) and unknown primary squamous cell carcinomas that are p16 and EBV-negative. Cutaneous squamous cell carcinoma of the head and neck included.

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)
- N2 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
- N2a Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)
- N2b Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-);
- N2c Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-);
- N3 Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or a single contralateral node of any size and ENE(+);
- N3a Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-);
- N3b Metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)

HPV-mediated (p16+) oropharyngeal carcinoma

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastasis in 4 or fewer lymph nodes
- N2 Metastasis in more than 4 lymph nodes

Nasopharyngeal carcinoma

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Unilateral metastasis in cervical lymph node(s) and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
- N2 Bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
- N3 Unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage

Mucosal melanoma

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Regional lymph node metastasis present

Cutaneous melanoma

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-);
- N2 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension, ENE(-)
- N2a Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)
- N2b Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)
- N2c Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-)
- N3 Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); or a single contralateral node of any size and ENE(+)
- N3a Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)
- N3b Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); or a single contralateral node of any size and ENE(+)

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media

S5.02 Year of publication and edition of cancer staging system

G5.01 **DIAGNOSTIC SUMMARY**
Include: Specimen(s) submitted and laterality; Tumour type; Lymph node status; Presence or absence of ENE; Margin of resection if ENE present; Tumour stage.

S5.03 OVERARCHING COMMENT

G5.02 Edition/version number of the Structured Reporting Protocol.